Sensible biotechnologies slashes time taken to optimize novel cell-based mrna therapeutics by more than 90% with ai platform built on nvidia technology

Boston--(business wire)--sensible biotechnologies are accelerating the development of their cell-based platform for next-generation mrna medicines with nvidia ai.
NVDA Ratings Summary
NVDA Quant Ranking